Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Activation of trace amine-associated receptor 1 attenuates schedule-induced polydipsia in rats.

Sukhanov I, Dorotenko A, Dolgorukova A, Hoener MC, Gainetdinov RR, Bespalov AY.

Neuropharmacology. 2018 Oct 24;144:184-192. doi: 10.1016/j.neuropharm.2018.10.034. [Epub ahead of print]

PMID:
30366004
2.

Novel translational rat models of dopamine transporter deficiency.

Leo D, Sukhanov I, Gainetdinov RR.

Neural Regen Res. 2018 Dec;13(12):2091-2093. doi: 10.4103/1673-5374.241453. No abstract available.

3.

Real-Time Accumbal Dopamine Response to Negative Stimuli: Effects of Ethanol.

Mikhailova MA, Deal AL, Grinevich VP, Bonin KD, Gainetdinov RR, Budygin EA.

ACS Chem Neurosci. 2018 Oct 17. doi: 10.1021/acschemneuro.8b00272. [Epub ahead of print]

PMID:
30289684
4.

Behavioral Effects of a Potential Novel TAAR1 Antagonist.

Lam VM, Mielnik CA, Baimel C, Beerepoot P, Espinoza S, Sukhanov I, Horsfall W, Gainetdinov RR, Borgland SL, Ramsey AJ, Salahpour A.

Front Pharmacol. 2018 Sep 4;9:953. doi: 10.3389/fphar.2018.00953. eCollection 2018.

5.

Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397.

Espinoza S, Leo D, Sotnikova TD, Shahid M, Kääriäinen TM, Gainetdinov RR.

Front Pharmacol. 2018 Jun 21;9:645. doi: 10.3389/fphar.2018.00645. eCollection 2018.

6.

Trace Amines and Their Receptors.

Gainetdinov RR, Hoener MC, Berry MD.

Pharmacol Rev. 2018 Jul;70(3):549-620. doi: 10.1124/pr.117.015305. Review.

PMID:
29941461
7.

Dopamine D2 Receptor Supersensitivity as a Spectrum of Neurotoxicity and Status in Psychiatric Disorders.

Kostrzewa RM, Wydra K, Filip M, Crawford CA, McDougall SA, Brown RW, Borroto-Escuela DO, Fuxe K, Gainetdinov RR.

J Pharmacol Exp Ther. 2018 Sep;366(3):519-526. doi: 10.1124/jpet.118.247981. Epub 2018 Jun 19.

PMID:
29921706
8.

Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases.

Schwartz MD, Canales JJ, Zucchi R, Espinoza S, Sukhanov I, Gainetdinov RR.

Expert Opin Ther Targets. 2018 Jun;22(6):513-526. doi: 10.1080/14728222.2018.1480723. Epub 2018 Jun 5.

PMID:
29798691
9.

The Effects of Chronic Amitriptyline on Zebrafish Behavior and Monoamine Neurochemistry.

Meshalkina DA, Kysil EV, Antonova KA, Demin KA, Kolesnikova TO, Khatsko SL, Gainetdinov RR, Alekseeva PA, Kalueff AV.

Neurochem Res. 2018 May 8. doi: 10.1007/s11064-018-2536-5. [Epub ahead of print]

PMID:
29740748
10.

Identification of TAAR5 Agonist Activity of Alpha-NETA and Its Effect on Mismatch Negativity Amplitude in Awake Rats.

Aleksandrov AA, Knyazeva VM, Volnova AB, Dmitrieva ES, Korenkova O, Espinoza S, Gerasimov A, Gainetdinov RR.

Neurotox Res. 2018 Oct;34(3):442-451. doi: 10.1007/s12640-018-9902-6. Epub 2018 May 1.

PMID:
29713997
11.

Trace Amine-Associated Receptor 1 Modulates the Locomotor and Sensitization Effects of Nicotine.

Sukhanov I, Dorofeikova M, Dolgorukova A, Dorotenko A, Gainetdinov RR.

Front Pharmacol. 2018 Apr 6;9:329. doi: 10.3389/fphar.2018.00329. eCollection 2018.

12.

Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models.

Zabegalov KN, Kolesnikova TO, Khatsko SL, Volgin AD, Yakovlev OA, Amstislavskaya TG, Alekseeva PA, Meshalkina DA, Friend AJ, Bao W, Demin KA, Gainetdinov RR, Kalueff AV.

Eur J Pharmacol. 2018 Jun 15;829:129-140. doi: 10.1016/j.ejphar.2018.04.003. Epub 2018 Apr 5. Review.

PMID:
29627310
13.

Interplay between the key proteins of serotonin system in SSRI antidepressants efficacy.

Kulikov AV, Gainetdinov RR, Ponimaskin E, Kalueff AV, Naumenko VS, Popova NK.

Expert Opin Ther Targets. 2018 Apr;22(4):319-330. doi: 10.1080/14728222.2018.1452912. Epub 2018 Apr 4.

PMID:
29542343
14.

Behavioral Phenotyping of Dopamine Transporter Knockout Rats: Compulsive Traits, Motor Stereotypies, and Anhedonia.

Cinque S, Zoratto F, Poleggi A, Leo D, Cerniglia L, Cimino S, Tambelli R, Alleva E, Gainetdinov RR, Laviola G, Adriani W.

Front Psychiatry. 2018 Feb 22;9:43. doi: 10.3389/fpsyt.2018.00043. eCollection 2018.

15.

Rational design, chemical synthesis and biological evaluation of novel biguanides exploring species-specificity responsiveness of TAAR1 agonists.

Guariento S, Tonelli M, Espinoza S, Gerasimov AS, Gainetdinov RR, Cichero E.

Eur J Med Chem. 2018 Feb 25;146:171-184. doi: 10.1016/j.ejmech.2018.01.059. Epub 2018 Feb 4.

PMID:
29407948
16.

Novelty-related behavior of young and adult dopamine transporter knockout rats: Implication for cognitive and emotional phenotypic patterns.

Adinolfi A, Carbone C, Leo D, Gainetdinov RR, Laviola G, Adriani W.

Genes Brain Behav. 2018 Apr;17(4):e12463. doi: 10.1111/gbb.12463. Epub 2018 Mar 22.

PMID:
29406596
17.

Pronounced Hyperactivity, Cognitive Dysfunctions, and BDNF Dysregulation in Dopamine Transporter Knock-out Rats.

Leo D, Sukhanov I, Zoratto F, Illiano P, Caffino L, Sanna F, Messa G, Emanuele M, Esposito A, Dorofeikova M, Budygin EA, Mus L, Efimova EV, Niello M, Espinoza S, Sotnikova TD, Hoener MC, Laviola G, Fumagalli F, Adriani W, Gainetdinov RR.

J Neurosci. 2018 Feb 21;38(8):1959-1972. doi: 10.1523/JNEUROSCI.1931-17.2018. Epub 2018 Jan 18.

18.

TAAR5 receptor agonist affects sensory gating in rats.

Aleksandrov AA, Dmitrieva ES, Volnova AB, Knyazeva VM, Gerasimov AS, Gainetdinov RR.

Neurosci Lett. 2018 Feb 14;666:144-147. doi: 10.1016/j.neulet.2017.12.053. Epub 2017 Dec 27.

PMID:
29288046
19.

The after-hours circadian mutant has reduced phenotypic plasticity in behaviors at multiple timescales and in sleep homeostasis.

Maggi S, Balzani E, Lassi G, Garcia-Garcia C, Plano A, Espinoza S, Mus L, Tinarelli F, Nolan PM, Gainetdinov RR, Balci F, Nieus T, Tucci V.

Sci Rep. 2017 Dec 19;7(1):17765. doi: 10.1038/s41598-017-18130-2.

20.

Human Accelerated Regions and Other Human-Specific Sequence Variations in the Context of Evolution and Their Relevance for Brain Development.

Levchenko A, Kanapin A, Samsonova A, Gainetdinov RR.

Genome Biol Evol. 2018 Jan 1;10(1):166-188. doi: 10.1093/gbe/evx240. Review.

21.

Psychedelic Drugs in Biomedicine.

Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV.

Trends Pharmacol Sci. 2017 Nov;38(11):992-1005. doi: 10.1016/j.tips.2017.08.003. Epub 2017 Sep 22. Review.

PMID:
28947075
22.

Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges.

Berry MD, Gainetdinov RR, Hoener MC, Shahid M.

Pharmacol Ther. 2017 Dec;180:161-180. doi: 10.1016/j.pharmthera.2017.07.002. Epub 2017 Jul 16. Review.

23.

No effect of C1473G polymorphism in the tryptophan hydroxylase 2 gene on the response of the brain serotonin system to chronic fluoxetine treatment in mice.

Bazhenova EY, Sinyakova NA, Kulikova EA, Kazarinova IA, Bazovkina DV, Gainetdinov RR, Kulikov AV.

Neurosci Lett. 2017 Jul 13;653:264-268. doi: 10.1016/j.neulet.2017.05.070. Epub 2017 Jun 1.

PMID:
28579486
24.

Recombinant Adeno-Associated Virus-mediated rescue of function in a mouse model of Dopamine Transporter Deficiency Syndrome.

Illiano P, Bass CE, Fichera L, Mus L, Budygin EA, Sotnikova TD, Leo D, Espinoza S, Gainetdinov RR.

Sci Rep. 2017 Apr 18;7:46280. doi: 10.1038/srep46280.

25.

Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons.

Bono F, Savoia P, Guglielmi A, Gennarelli M, Piovani G, Sigala S, Leo D, Espinoza S, Gainetdinov RR, Devoto P, Spano P, Missale C, Fiorentini C.

Mol Neurobiol. 2018 Feb;55(2):1054-1067. doi: 10.1007/s12035-016-0376-3. Epub 2017 Jan 14.

PMID:
28092083
26.

Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy.

Polanco MJ, Parodi S, Piol D, Stack C, Chivet M, Contestabile A, Miranda HC, Lievens PM, Espinoza S, Jochum T, Rocchi A, Grunseich C, Gainetdinov RR, Cato AC, Lieberman AP, La Spada AR, Sambataro F, Fischbeck KH, Gozes I, Pennuto M.

Sci Transl Med. 2016 Dec 21;8(370):370ra181. doi: 10.1126/scitranslmed.aaf9526.

PMID:
28003546
27.

Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.

Tonelli M, Espinoza S, Gainetdinov RR, Cichero E.

Eur J Med Chem. 2017 Feb 15;127:781-792. doi: 10.1016/j.ejmech.2016.10.058. Epub 2016 Oct 27.

PMID:
27823885
28.

Hit-to-Lead Optimization of Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists with a Diphenylmethane-Scaffold: Design, Synthesis, and Biological Study.

Chiellini G, Nesi G, Sestito S, Chiarugi S, Runfola M, Espinoza S, Sabatini M, Bellusci L, Laurino A, Cichero E, Gainetdinov RR, Fossa P, Raimondi L, Zucchi R, Rapposelli S.

J Med Chem. 2016 Nov 10;59(21):9825-9836. Epub 2016 Oct 21.

PMID:
27731647
29.

A Caenorhabditis elegans model to study dopamine transporter deficiency syndrome.

Illiano P, Lanzo A, Leo D, Paglione M, Zampi G, Gainetdinov RR, Di Schiavi E.

Eur J Neurosci. 2017 Jan;45(1):207-214. doi: 10.1111/ejn.13366. Epub 2016 Sep 2.

PMID:
27519790
30.

Optogenetically-induced tonic dopamine release from VTA-nucleus accumbens projections inhibits reward consummatory behaviors.

Mikhailova MA, Bass CE, Grinevich VP, Chappell AM, Deal AL, Bonin KD, Weiner JL, Gainetdinov RR, Budygin EA.

Neuroscience. 2016 Oct 1;333:54-64. doi: 10.1016/j.neuroscience.2016.07.006. Epub 2016 Jul 13.

31.

Cross-hemispheric dopamine projections have functional significance.

Fox ME, Mikhailova MA, Bass CE, Takmakov P, Gainetdinov RR, Budygin EA, Wightman RM.

Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):6985-90. doi: 10.1073/pnas.1603629113. Epub 2016 Jun 13.

32.

Dopamine transporter mutant animals: a translational perspective.

Efimova EV, Gainetdinov RR, Budygin EA, Sotnikova TD.

J Neurogenet. 2016 Mar;30(1):5-15. doi: 10.3109/01677063.2016.1144751. Review.

33.

G protein-coupled receptor kinases as regulators of dopamine receptor functions.

Gurevich EV, Gainetdinov RR, Gurevich VV.

Pharmacol Res. 2016 Sep;111:1-16. doi: 10.1016/j.phrs.2016.05.010. Epub 2016 May 10. Review.

34.

Genetic and environmental modulation of neurodevelopmental disorders: Translational insights from labs to beds.

Homberg JR, Kyzar EJ, Scattoni ML, Norton WH, Pittman J, Gaikwad S, Nguyen M, Poudel MK, Ullmann JF, Diamond DM, Kaluyeva AA, Parker MO, Brown RE, Song C, Gainetdinov RR, Gottesman II, Kalueff AV.

Brain Res Bull. 2016 Jul;125:79-91. doi: 10.1016/j.brainresbull.2016.04.015. Epub 2016 Apr 23. Review.

PMID:
27113433
35.

Understanding autism and other neurodevelopmental disorders through experimental translational neurobehavioral models.

Homberg JR, Kyzar EJ, Nguyen M, Norton WH, Pittman J, Poudel MK, Gaikwad S, Nakamura S, Koshiba M, Yamanouchi H, Scattoni ML, Ullman JF, Diamond DM, Kaluyeva AA, Parker MO, Klimenko VM, Apryatin SA, Brown RE, Song C, Gainetdinov RR, Gottesman II, Kalueff AV.

Neurosci Biobehav Rev. 2016 Jun;65:292-312. doi: 10.1016/j.neubiorev.2016.03.013. Epub 2016 Apr 2. Review.

PMID:
27048961
36.

Increased context-dependent conditioning to amphetamine in mice lacking TAAR1.

Sukhanov I, Caffino L, Efimova EV, Espinoza S, Sotnikova TD, Cervo L, Fumagalli F, Gainetdinov RR.

Pharmacol Res. 2016 Jan;103:206-14. doi: 10.1016/j.phrs.2015.11.002. Epub 2015 Dec 2.

PMID:
26640076
37.

Rapid Conversion of Fibroblasts into Functional Forebrain GABAergic Interneurons by Direct Genetic Reprogramming.

Colasante G, Lignani G, Rubio A, Medrihan L, Yekhlef L, Sessa A, Massimino L, Giannelli SG, Sacchetti S, Caiazzo M, Leo D, Alexopoulou D, Dell'Anno MT, Ciabatti E, Orlando M, Studer M, Dahl A, Gainetdinov RR, Taverna S, Benfenati F, Broccoli V.

Cell Stem Cell. 2015 Dec 3;17(6):719-734. doi: 10.1016/j.stem.2015.09.002. Epub 2015 Oct 29.

38.

In-vivo pharmacology of Trace-Amine Associated Receptor 1.

Lam VM, Espinoza S, Gerasimov AS, Gainetdinov RR, Salahpour A.

Eur J Pharmacol. 2015 Sep 15;763(Pt B):136-42. doi: 10.1016/j.ejphar.2015.06.026. Epub 2015 Jun 17. Review.

PMID:
26093041
39.

Design, Synthesis, and Evaluation of Thyronamine Analogues as Novel Potent Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists.

Chiellini G, Nesi G, Digiacomo M, Malvasi R, Espinoza S, Sabatini M, Frascarelli S, Laurino A, Cichero E, Macchia M, Gainetdinov RR, Fossa P, Raimondi L, Zucchi R, Rapposelli S.

J Med Chem. 2015 Jun 25;58(12):5096-107. doi: 10.1021/acs.jmedchem.5b00526. Epub 2015 Jun 5.

PMID:
26010728
40.

Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.

Urs NM, Bido S, Peterson SM, Daigle TL, Bass CE, Gainetdinov RR, Bezard E, Caron MG.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):E2517-26. doi: 10.1073/pnas.1502740112. Epub 2015 Apr 27.

41.

The trace amine-associated receptor 1 modulates methamphetamine's neurochemical and behavioral effects.

Cotter R, Pei Y, Mus L, Harmeier A, Gainetdinov RR, Hoener MC, Canales JJ.

Front Neurosci. 2015 Feb 13;9:39. doi: 10.3389/fnins.2015.00039. eCollection 2015.

42.

TAAR1 Modulates Cortical Glutamate NMDA Receptor Function.

Espinoza S, Lignani G, Caffino L, Maggi S, Sukhanov I, Leo D, Mus L, Emanuele M, Ronzitti G, Harmeier A, Medrihan L, Sotnikova TD, Chieregatti E, Hoener MC, Benfenati F, Tucci V, Fumagalli F, Gainetdinov RR.

Neuropsychopharmacology. 2015 Aug;40(9):2217-27. doi: 10.1038/npp.2015.65. Epub 2015 Mar 9.

43.

Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1.

Espinoza S, Ghisi V, Emanuele M, Leo D, Sukhanov I, Sotnikova TD, Chieregatti E, Gainetdinov RR.

Neuropharmacology. 2015 Jun;93:308-13. doi: 10.1016/j.neuropharm.2015.02.010. Epub 2015 Feb 24.

PMID:
25721394
44.

Dopamine receptors - IUPHAR Review 13.

Beaulieu JM, Espinoza S, Gainetdinov RR.

Br J Pharmacol. 2015 Jan;172(1):1-23. Review.

45.

G protein-coupled receptor kinases: from molecules to diseases.

Gurevich EV, Premont RT, Gainetdinov RR.

FASEB J. 2015 Feb;29(2):361-4. doi: 10.1096/fj.14-263657ufm. No abstract available.

46.

Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.

Masoud ST, Vecchio LM, Bergeron Y, Hossain MM, Nguyen LT, Bermejo MK, Kile B, Sotnikova TD, Siesser WB, Gainetdinov RR, Wightman RM, Caron MG, Richardson JR, Miller GW, Ramsey AJ, Cyr M, Salahpour A.

Neurobiol Dis. 2015 Feb;74:66-75. doi: 10.1016/j.nbd.2014.10.016. Epub 2014 Oct 30.

47.

Exogenous α-synuclein decreases raft partitioning of Cav2.2 channels inducing dopamine release.

Ronzitti G, Bucci G, Emanuele M, Leo D, Sotnikova TD, Mus LV, Soubrane CH, Dallas ML, Thalhammer A, Cingolani LA, Mochida S, Gainetdinov RR, Stephens GJ, Chieregatti E.

J Neurosci. 2014 Aug 6;34(32):10603-15. doi: 10.1523/JNEUROSCI.0608-14.2014.

48.

Remote control of induced dopaminergic neurons in parkinsonian rats.

Dell'Anno MT, Caiazzo M, Leo D, Dvoretskova E, Medrihan L, Colasante G, Giannelli S, Theka I, Russo G, Mus L, Pezzoli G, Gainetdinov RR, Benfenati F, Taverna S, Dityatev A, Broccoli V.

J Clin Invest. 2014 Jul;124(7):3215-29. doi: 10.1172/JCI74664. Epub 2014 Jun 17.

49.

TAAR1-dependent effects of apomorphine in mice.

Sukhanov I, Espinoza S, Yakovlev DS, Hoener MC, Sotnikova TD, Gainetdinov RR.

Int J Neuropsychopharmacol. 2014 Oct;17(10):1683-93. doi: 10.1017/S1461145714000509. Epub 2014 Jun 13.

PMID:
24925023
50.

Further insights into the pharmacology of the human trace amine-associated receptors: discovery of novel ligands for TAAR1 by a virtual screening approach.

Cichero E, Espinoza S, Franchini S, Guariento S, Brasili L, Gainetdinov RR, Fossa P.

Chem Biol Drug Des. 2014 Dec;84(6):712-20. doi: 10.1111/cbdd.12367. Epub 2014 Jun 30.

PMID:
24894156

Supplemental Content

Loading ...
Support Center